dataset · Zenodo (CERN European Organization for Nuclear Research)
Supporting Information for: Integrated In Silico Discovery of Thymoquinone Analogs Targeting the Keap1--Nrf2 Pathway for Amyotrophic Lateral Sclerosis Therapy Authors: Jabir C. Nalicho*, Petro E. Mabeyo, Andrew S. Paluch, and Lucas Paul** Contact information: * jabir.chande@gmail.com** lucas.paul@udsm.ac.tz Journal: ChemistryOpen Date: 4 February 2026 Description: CSV file (Table_S1_Thymoquinone_Analogues_Predicted_Activities.csv) with predicted pIC50 values, activity classes, leverage values, and applicability domain (AD) status for 64 thymoquinone analogues generated using the validated AtomPairs2DCount QSAR model.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.5281/zenodo.18483747
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
